Pramipexole Articles
Variations in Parkinson's disease treatment among prescribers in France, Germany, Italy, Spain and the UK
2 December 2010
US uptake of Boehringer Ingelheim’s Mirapex ER for Parkinson's disease will be inhibited by generic pramipexole
1 April 2010
US FDA approves Boehringer Ingelheim’s once-daily Mirapex ER for early Parkinson's disease and Gilead’s Cayston for cystic fibrosis
23 February 2010
Mylan confirms first-to-file patent challenge to Cephalon’s sleep-disorder drug Nuvigil
12 January 2010
Drug candidates in pipeline offer potential for Parkinson's disease market, says Frost & Sullivan
9 December 2009
Boehringer Ingelheim’s prolonged-release Mirapexin/Sifrol gets EU clearance for Parkinson’s disease
15 October 2009
Boeh Ing RLS drug comparable to placebo
5 May 2009
Boehringer's 2008 net sales jump 6.4%
24 April 2009
BI sponsors RLS web site for World Sleep Day
23 March 2009
Azilect helps "double 2nd-line MAO-Bs in PD"
16 March 2009
Pramipexole benefits RLS patients on multiple endpoints
8 September 2008
PROUD trial due to show results in 2009
8 September 2008
PDCO gives word on PIPs from latest meeting
1 September 2008
CHMP gives nod to Krka's generic Sifrol
7 July 2008
BI's PD drug finally gets on Australian PBS
16 June 2008
Boehringer Ingelheim RLS study results
16 June 2008
Pramipexole reduces sleep disturbance in RLS
28 April 2008
Spiriva and Micardis boost Boehringer's 2007 sales 8.8%, as profit jumps 4.8% to $2.8M
14 April 2008
Depression prevalent in PD, says study
10 September 2007
Boeh Ing's 1st half 2007 sales up 2.1%
6 August 2007
Pramipexole: broad effectiveness in RLS
18 June 2007
Boeh Ingelheim sales leap 17.3% in Japan
23 April 2007
BI meeting discusses depression's role in PD
19 February 2007
Strong data for BI's pramipexole in broad range of RLS patients, even those with concomitant diseases
6 November 2006
Boeh Ing reports strong mood data for RLS drug
11 September 2006
Mirapexin improves RLS symptoms
26 June 2006
Boehringer Ingelheim: strong data for pramipexole in RLS
10 April 2006
BI's pramipexole shows promise as RLS therapy
4 July 2005
Encouraging data for BI's RLS drug
14 March 2005
BI regains pramipexole product portfolio
25 October 2004
Parkinson's drugs may slow progression
22 April 2002
Pramipexole cleared as monotherapy in PD
26 November 2001
Pharmacia/BI's Mirapex shows less risk of motor complications
19 October 2000
Pharmacia/BI's Mirapex shows less risk of motor complications
19 October 2000
First-half sales rise 19% at Boeh Ingelheim
25 August 2000
Pharmacia's DAs as first-line therapy in PD
20 June 2000
Euro neurodegenerative disease markets
24 February 1999
Neurodegenerative disease markets in Europe
19 February 1999
P&U posts strong growth for 1998
12 February 1999
Mirapex May Help PD Tremor, Say New Data
18 June 1998
EMEA CPMP Plenary Meeting In February
10 March 1998
Pramipexole Approved In The European Union
5 March 1998
1997: Another Good Year For New Chemical Entities
6 January 1998
Massive Growth For Parkinson's Market
8 December 1997
1998 - A "Critical" Year For P&U, Says CEO
3 December 1997
Pramipexole Approved By The EMEA
23 October 1997
Mirapex Cuts Levodopa Reliance
25 September 1997
First Launch For P&U's Edronax
31 July 1997
Entacapone And Tolcapone Near Market Introduction
26 March 1997
P&U Launches Dostinex In The USA
20 March 1997
Roche Enters New Product Phase With Bright Prospects
17 February 1997
P&U Moves To Revamp Inherited Pipeline
3 June 1996
Pharmacia & Upjohn First Combined Results
26 February 1996
P&U Files In USA For Parkinson's Drug
15 January 1996
Two More Launches For Upjohn's Freedox
24 April 1995
UPJOHN OUTLINES STRATEGIC DIRECTIONS
18 April 1994
Showing 1-72 of 72 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
